Keeping aside the role of IL-1β protein as a potential therapeutic target for dry eye disease and COVID-19, its inhibitors have also been implicated to have a central role in the treatment of myeloma, rheumatoid arthritis, amyotrophic lateral sclerosis (ALS), etc. [27,28,29,30]. This evidence concerns the gene IL1B and COVID-19.